GM-5022

GM-5022
Clinical data
Other namesGM5022
Routes of
administration		Oral[1][2][3]
Drug classPsychoplastogen
ATC code
  • None

GM-5022 is a non-hallucinogenic psychoplastogen which is under development for the treatment of depressive, anxiety, and other neurological disorders.[1][4][2][5][6][3] It is taken orally.[1][2][3] The drug's specific mechanism of action and chemical structure do not appear to have been disclosed yet.[1][4] GM-5022 is under development by Gilgamesh Pharmaceuticals.[1][4] As of December 2024, it is in the preclinical research stage of development, with an Investigational New Drug (IND) application being worked on.[1][4][3]

See also

References

  1. ^ a b c d e f "GM 5022". AdisInsight. Springer Nature Switzerland AG. 4 December 2024. Retrieved 1 August 2025.
  2. ^ a b c "Gilgamesh Pharma". The Psychedelic Pulse. 11 July 2024. Retrieved 1 August 2025. GM-5022: In the IND enabling phase, this oral neuroplastogen aims to treat depression and anxiety without causing hallucinations. It represents a new class of treatments that could significantly improve patient outcomes.
  3. ^ a b c d Barrie R (14 May 2024). "AbbVie makes a play for psychiatric treatments with $2bn Gilgamesh collaboration". Pharmaceutical Technology. Retrieved 1 August 2025. The pharma company is also working on an investigational new drug (IND) application for an oral non-hallucinogenic neuroplastogen named GM-5022.
  4. ^ a b c d "Delving into the Latest Updates on GM-5022 with Synapse". Synapse. 8 May 2025. Retrieved 1 August 2025.
  5. ^ Bratulic A (13 May 2024). "AbbVie wagers up to $2B on Gilgamesh's approach to psychedelics – minus the trip". firstwordpharma.com. Retrieved 1 August 2025. Gilgamesh's internal pipeline features one neuroplastogen: GM-5022, an oral non-hallucinogenic compound in early development for depression and anxiety.
  6. ^ Barton C (31 July 2025). "Neuroplastogens: A novel approach to treat neurological diseases". pharmaphorum. Retrieved 1 August 2025. GM-5022, a pre-clinical non-hallucinogenic oral neuroplastogen in development for depression, anxiety, and other mental health disorders.


This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.